Ascentage Pharma Group International (AAPG)

On January 14, Rodman & Renshaw initiated coverage of Ascentage Pharma Group International (NASDAQ:AAPG) with a Buy rating and a $48 price target, citing the company’s differentiated hematology-focused...

Investing in healthcare stocks offers a combination of defensive stability and long-term growth potential, supported by consistent demand for medical services, pharmaceuticals, and healthcare technologies...

Ascentage Pharma Group International (NASDAQ:AAPG) is one of the best performing mid cap stocks so far in 2025.

On July 1, Alan McKnight, the CIO at Regions Wealth Management, appeared on CNBC to explain how his biggest worry is currently centered around uncertainty, which he believes leads to volatility.

Ascentage Pharma Group International (NASDAQ:AAPG) is one of the best young stocks to buy and hold for 5 years.

On July 2, Abby Yoder, JPMorgan Private Bank's chief equity strategist, joined CNBC's 'Closing Bell' to discuss the market's momentum in the second half of 2025.